Daneshvar, Kaveh http://orcid.org/0000-0002-7863-0489
Ardehali, M. Behfar
Klein, Isaac A.
Hsieh, Fu-Kai
Kratkiewicz, Arcadia J.
Mahpour, Amin http://orcid.org/0000-0001-5885-1340
Cancelliere, Sabrina O. L. http://orcid.org/0000-0002-7946-2376
Zhou, Chan
Cook, Brett M.
Li, Wenyang
Pondick, Joshua V.
Gupta, Sweta K. http://orcid.org/0000-0002-7157-8956
Moran, Sean P.
Young, Richard A. http://orcid.org/0000-0001-8855-8647
Kingston, Robert E.
Mullen, Alan C. http://orcid.org/0000-0002-4096-3106
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Institute of Diabetes and Digestive and Kidney Diseases (5R01HD09277304)
Article History
Received: 1 April 2019
Accepted: 5 August 2020
First Online: 7 September 2020
Competing interests
: A.C.M. receives research funding from Boehringer Ingelheim, Bristol-Myers Squibb, Roche Pharmaceuticals and Takeda Pharmaceuticals for unrelated projects. R.A.Y. is a founder and shareholder of Syros Pharmaceuticals, Camp4 Therapeutics, Dewpoint Therapeutics and Omega Therapeutics. I.A.K. is a consultant and a shareholder of Dewpoint Therapeutics.